MUC16 and neoplasm: We have previously published a second generation CD28ζ co-stimulated CAR-T cell targeting the tumor retained portion of Muc16/CA-125 (Lee et al., 2024) (4H11) and generated armored versions expressing CCR2b (4H11-CCR2) and CCR5 (4H11-CCR5) (Figure 3A).